根治性治疗后非小细胞肺癌的循环肿瘤DNA微小残留病灶检测
综述总结根治性治疗后非小细胞肺癌(NSCLC)循环肿瘤DNA(ctDNA)微小残留病灶(MRD)检测的证据,显示治疗后首次检测预测复发的敏感性36%–100%、特异性71%–100%,全部随访时间点敏感性82%–100%、特异性70%–100%,并介绍正在进行的前瞻性研究。
要点
- 根治性治疗后首次ctDNA MRD检测预测复发敏感性36%–100%、特异性71%–100%。
- 全部随访时间点检测敏感性82%–100%、特异性70%–100%。
- 现有研究样本量有限、多为回顾性、缺乏充分前瞻性临床验证。
核心结论
- ctDNA MRD是有潜力改善NSCLC生存结局的生物标志物。
- 现有证据多来自样本量有限、多为回顾性的研究,缺乏充分前瞻性临床验证。
研究设计与样本
- 综述总结根治性治疗后NSCLC患者ctDNA MRD检测的现有证据及正在进行的前瞻性研究。
- 现有研究多为回顾性、样本量有限,采用基于二代测序的血浆游离DNA检测。
主要发现
- 仅限治疗后首次时间点评估时,ctDNA MRD检测预测疾病复发的敏感性为36%–100%,特异性为71%–100%。
- 考虑所有治疗后随访时间点(监测)时,识别复发的敏感性为82%–100%,特异性为70%–100%。
关键数值与推荐
- 治疗后首次时间点:预测复发敏感性36%–100%,特异性71%–100%。
- 全部随访时间点:识别复发敏感性82%–100%,特异性70%–100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 现有研究样本量有限、多为回顾性,缺乏充分前瞻性临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer (NSCLC). Multiple groups have shown the ability to detect MRD following curative-intent NSCLC treatment using next-generation sequencing-based assays of plasma cell-free DNA. These studies have been modest in size, largely retrospective, and without thorough prospective clinical validation. Still, when restricting measurement to the first post-treatment timepoint to assess the clinical performance of ctDNA MRD detection, they have demonstrated sensitivity for predicting disease relapse ranging between 36% and 100%, and specificity ranging between 71% and 100%. When considering all post-treatment follow-up timepoints (surveillance), including those beyond the initial post-treatment measurement, these assays' performances improve with sensitivity and specificity for identifying relapse ranging from 82% to 100% and 70% to 100%, respectively. In this manuscript, we review the evidence available to date regarding ctDNA MRD detection in patients with NSCLC undergoing curative-intent treatment and the ongoing prospective studies involving ctDNA MRD detection in this patient population.
引用
- Pellini B, Chaudhuri AA. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. J Clin Oncol. 2022. PMID: 34985936. doi:10.1200/JCO.21.01929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。